Ceretas hits key device milestone as $693,000 grant tranche moves closer

Ceretas has cleared the third milestone of its government-backed development program, unlocking a final non-dilutive funding tranche of $692,578 and delivering functional prototypes of two components designed to make its therapeutic ultrasound platform easier and cheaper to operate.

For investors, the significance extends beyond the grant cheque. The work targets two decidedly practical issues in medical device development: how many people are needed to operate the system and how much the finished product costs to manufacture.

Ceretas is developing a portable, non-invasive therapeutic ultrasound platform aimed initially at Alzheimer's disease and other neurodegenerative conditions. The technology uses low-intensity focused ultrasound directed through the skull, with potential applications spanning neuromodulation and opening of the blood-brain barrier.

The company completed the latest milestone on schedule under the CUREator+ Dementia & Cognitive Decline program. Fully functional prototypes of an internally developed image-guided neuronavigation system and a lift assist device have now been delivered and accepted by Brandon BioCatalyst.

$2.4 million grant provides non-dilutive development runway

Ceretas was awarded $2.4 million in July 2025 through the CUREator+ program, which is backed by the Australian Government's Medical Research Future Fund BioMedTech Incubator initiative.

Completion of the latest milestone triggers the final $692,578 tranche, expected in coming weeks.

That matters because the funding is non-dilutive. For an early-stage medical technology company, development programs can consume considerable capital well before product revenues emerge. Grant funding allows Ceretas to progress engineering work without issuing additional shares specifically to fund these activities.

It does not remove the broader funding question that accompanies clinical-stage companies, but it does mean a meaningful slice of device development has been externally funded rather than borne entirely by shareholders.

The broader CUREator-supported development program remains scheduled for completion by mid-2027.

Cutting the operator requirement from two to one

The most commercially relevant aspect of the engineering program may be Ceretas' move to develop its own image-guided neuronavigation software.

Neuronavigation allows clinicians to target specific regions of the brain accurately during treatment. Ceretas currently uses an off-the-shelf system, but its proprietary version is intended to reduce the number of operators required from two to one while improving usability and reducing cost of goods.

That is not merely an ergonomic tweak.

Medical technologies ultimately need to fit into real clinical workflows. A device requiring two trained operators can carry higher labour costs and create more logistical friction than one designed for a single operator. If Ceretas can achieve the intended workflow improvement while maintaining accuracy, it could make eventual deployment more practical.

The company has not yet quantified the expected reduction in manufacturing costs or operating expenses, so investors cannot put a dollar value on those improvements at this stage.

Chief executive and managing director Dr Rachel de las Heras said developing the company's own neuronavigation capability would allow Ceretas to customise the clinician experience and provide "an easy-to-use, efficient tool to plan treatment and perform ultrasound sonication accurately".

Lift assist device tackles another practical hurdle

The second prototype is a lift assist mechanism designed to help position the ultrasound probe accurately and steadily on a patient's head.

Ceretas developed the component with Melbourne-based medtech product development group Planet Innovation.

The concept sounds less glamorous than ultrasound interacting with the brain, but successful medical devices often depend as much on mechanical usability as scientific sophistication. Consistent positioning, ease of operation and repeatable treatment delivery can all become important considerations as a technology moves from research environments towards larger clinical studies and potentially routine care.

The rendering released by Ceretas shows the planned system incorporating the neuronavigation interface, lift assist assembly and ultrasound trolley into a single treatment setup. The design remains a prototype and is subject to change.

Clinical trials remain the bigger value test

The engineering milestone is useful progress, but investors should distinguish device optimisation from clinical validation.

Ceretas' technology stems from more than a decade of research at the University of Queensland and Queensland Brain Institute. A first-in-human Phase 1 study involving 12 Alzheimer's participants was completed in 2024, with the treatment reported as fast, safe and well tolerated and with encouraging early behavioural signals. Results were published in Brain Communications in December 2025.

Ceretas is now preparing to commence the Phase 2 CERE-CALM study in Alzheimer's patients experiencing behavioural and psychological symptoms of dementia.

Separately, Queensland Brain Institute researchers are conducting the Phase 2 AGIFUS trial using the same underlying technology in Alzheimer's-related agitation, with independent funding from Queensland Health.

Those clinical programs are likely to provide far more consequential evidence about the platform's therapeutic potential than an engineering milestone alone.

What investors should watch next

The near-term catalyst is straightforward: receipt of the $692,578 final funding tranche.

Beyond that, attention shifts to completion of the next-generation device program by mid-2027 and progress towards Phase 2 clinical evaluation.

Ceretas has now demonstrated that it can deliver the engineering milestones attached to its government-backed funding program on schedule. The next challenge is converting those engineering advances into a system that is not only easier and cheaper to use, but also capable of producing persuasive clinical outcomes.

For a company attempting to bring therapeutic ultrasound into Alzheimer's treatment, the science remains the headline act. But reducing operator numbers, simplifying workflow and lowering device costs are the sort of less glamorous details that can determine whether promising technology ever makes it beyond the laboratory.